These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 28232371)
1. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells. David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371 [TBL] [Abstract][Full Text] [Related]
2. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782 [TBL] [Abstract][Full Text] [Related]
3. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice. Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028 [TBL] [Abstract][Full Text] [Related]
4. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149 [TBL] [Abstract][Full Text] [Related]
5. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53. Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104 [TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Kilger E; Kieser A; Baumann M; Hammerschmidt W EMBO J; 1998 Mar; 17(6):1700-9. PubMed ID: 9501091 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity. Tomlin JL; Guinn BA; Penn LZ; Berinstein NL Leuk Lymphoma; 2005 Apr; 46(4):581-92. PubMed ID: 16019487 [TBL] [Abstract][Full Text] [Related]
9. Bptf determines oncogenic addiction in aggressive B-cell lymphomas. Richart L; Felipe I; Delgado P; Andrés MP; Prieto J; Pozo ND; García JF; Piris MA; Ramiro A; Real FX Oncogene; 2020 Jun; 39(25):4884-4895. PubMed ID: 32451433 [TBL] [Abstract][Full Text] [Related]
10. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. D'Souza BN; Edelstein LC; Pegman PM; Smith SM; Loughran ST; Clarke A; Mehl A; Rowe M; Gélinas C; Walls D J Virol; 2004 Feb; 78(4):1800-16. PubMed ID: 14747545 [TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation. Arunkumar N; Liu C; Hang H; Song W Cell Mol Immunol; 2013 Jul; 10(4):360-72. PubMed ID: 23727784 [TBL] [Abstract][Full Text] [Related]
14. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch. Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983 [TBL] [Abstract][Full Text] [Related]
15. The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. Shkoda A; Town JA; Griese J; Romio M; Sarioglu H; Knöfel T; Giehler F; Kieser A PLoS Biol; 2012; 10(8):e1001376. PubMed ID: 22904686 [TBL] [Abstract][Full Text] [Related]
16. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010 [TBL] [Abstract][Full Text] [Related]
17. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747 [TBL] [Abstract][Full Text] [Related]
18. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas. Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597 [TBL] [Abstract][Full Text] [Related]
19. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Izumi KM; Cahir McFarland ED; Ting AT; Riley EA; Seed B; Kieff ED Mol Cell Biol; 1999 Aug; 19(8):5759-67. PubMed ID: 10409763 [TBL] [Abstract][Full Text] [Related]
20. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Pajic A; Staege MS; Dudziak D; Schuhmacher M; Spitkovsky D; Eissner G; Brielmeier M; Polack A; Bornkamm GW Int J Cancer; 2001 Sep; 93(6):810-6. PubMed ID: 11519042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]